Blockade of Hypocretin Receptor-1 Preferentially Prevents Cocaine Seeking: Comparison with Natural Reward Seeking
Overview
Authors
Affiliations
Hypothalamic orexin/hypocretin (Orx/Hcrt) peptides participate in the regulation of a wide range of physiological processes and are recruited by drugs of abuse. To advance our understanding of the potential of the Orx/Hcrt receptor-1 (Hcrt-r1) as a treatment target for cocaine addiction, the effect of SB334867 [N-(2-methyl-6-benzoxazolyl)-N'-1,5-n-aphthyridin-4-yl urea], a specific Hcrt-r1 antagonist, on reinstatement elicited by cocaine-associated stimuli versus stimuli associated with a highly palatable conventional reinforcer [sweetened condensed milk (SCM)] was tested. Two separate groups of male Wistar rats were trained to associate a discriminative stimulus (S⁺) with the response-contingent availability of cocaine (0.25 mg/0.1 ml/infusion) or SCM [2/1 (v/v)] and subjected to reinstatement tests following extinction of cocaine-reinforced or SCM-reinforced behavior, during which the reinforcers and S⁺ were withheld. Following extinction, presentation of the cocaine or SCM S⁺ produced comparable recovery of responding. Hcrt-r1 blockade by SB334867 (1-10 mg/kg, intraperitoneal) dose-dependently and selectively reversed conditioned reinstatement induced by cocaine-related stimuli, without interfering with reward seeking produced by the same stimulus when conditioned to SCM. The findings suggest an important role for Hcrt-r1 in appetitive behavior controlled by reward-related stimuli with selectivity for cocaine seeking and identify Hcrt-r1 as a potential treatment target for cocaine relapse prevention.
Hinds N, Wojtas I, Pulley D, McDonald S, Spencer C, Sudarikov M bioRxiv. 2025; .
PMID: 39896664 PMC: 11785129. DOI: 10.1101/2025.01.22.634146.
Illenberger J, Flores-Ramirez F, Pascasio G, Franco M, Mendonsa B, Martin-Fardon R J Psychopharmacol. 2024; 38(7):647-660.
PMID: 38888086 PMC: 11407285. DOI: 10.1177/02698811241260989.
Machine learning models to predict ligand binding affinity for the orexin 1 receptor.
Zhang V, OConnor S, Welsh W, James M Artif Intell Chem. 2024; 2(1).
PMID: 38476266 PMC: 10927255. DOI: 10.1016/j.aichem.2023.100040.
Illenberger J, Flores-Ramirez F, Matzeu A, Mason B, Martin-Fardon R Front Pharmacol. 2023; 14:1127735.
PMID: 37180716 PMC: 10172671. DOI: 10.3389/fphar.2023.1127735.
Brown R, James M Prog Neuropsychopharmacol Biol Psychiatry. 2023; 123:110717.
PMID: 36623582 PMC: 10162020. DOI: 10.1016/j.pnpbp.2023.110717.